27-Oct-2026 21:14:22

PIRAMAL PHARMA Q2 FY27 (CONS.) ; NET PROFIT AT ₹5.03 CR VS LOSS OF ₹99.22 CR (YOY), LOSS OF ₹69.38 CR (QOQ)

REVENUE UP 28.05% AT ₹2,617.06 CR (YOY), UP 15.29% (QOQ) EBITDA UP 119.76% AT ₹348.74 CR (YOY), UP 78.66% (QOQ) MARGINS AT 13.33% VS 7.76% (YOY), 8.60% (QOQ)

PIRAMAL PHARMA LIMITED

← Back to feed